Thursday, 23 Jan 2020

You are here

Outcomes of Systemic Sclerosis Hospitalization

A study of inpatient systemic sclerosis (SSc) hospitalizations using the 2012–13 National Inpatient Sample database finds an inpatient mortality rate of 5%, and that infection was the most common cause of SSc hospitalizations and in-hospital death.

Researchers from Pennsylvania calculated rates of hospitalization, in-hospital mortality, LOS and hospital costs from 9731 SSc hospitalizations; a sample from an estimated 48 655 nationwide SSc hospitalizations.

Hospitalized patients were predominantly older (63.2 years), female (82.2%) and Caucasian (71.5%).

Infection was the most common cause for SSc hospitalizations (17.4%) and for those who died (32.7%).

Hospital mortality was also associated with acute renal failure (aOR = 4.3, 95% CI: 3.3, 5.60 and aspiration (aOR= 3.5, 95% CI: 2.5, 4.9).

While the median length of stay (LOS) was 4 days, this was significantly prolonged by pulmonary fibrosis, and myositis, infection, acute renal failure, acute bowel obstruction and aspiration (aOR > 2.0 with P < 0.0001).

Higher cost of hospitalization  was predicted by acute renal failure, acute bowel obstruction, and aspiration.

SSc patients are at risk for significant morbidity and mortality, especially if hospitalized with infection or other complications of SSc.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.